Genome Integrity & Epigenetics (Collaborator)
P97-UFD1-LARP1 axis regulates autophagy and PARP inhibitor resistance in ovarian cancer
The student will have the opportunity to work across two labs: the Ramadan lab with an expertise in basic biology and the p97/degradation system and the Blagden lab with expertise in LARP biology and a strong translational emphasis. This will provide the trained with a true “bench to bedside” experience.
NuTIDE:701: A two-part, Phase 1 open-label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-7738, a nucleotide analogue, in participants with advanced solid tumours.
RDXC004/0001: A Modular, Multi-arm, Multi-part, Phase 1/2a, Adaptive Design Study to Evaluate the Safety and Tolerability of RXC004, Alone and in Combination with Anti-cancer Treatments, in Patients with Advanced Malignancies
BGB149-102: A Phase 1b, Multicentre, Multiple Ascending Dose, Safety, Pharmacokinetic and
Pharmacodynamic Study of Tilvestamab (BGB149) in Relapsed AXL-positive, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Patients
NX-1607-101: A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
NuTide 302: A Phase Ib open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment.
ASTX029-01: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
ART0380/REFMAL: A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
UCB6114: Phase 1/2 Open-Label, Multicentre Study To Assess The Safety, Pharmacokinetics and Anti-tumor Activity of UCB6114 Administered Intravenously To Participants With Advanced Solid Tumors.
Professor of Experimental Oncology
- Lead for Oxford Cancer Trials Office (OCTO)
- Chair of Athena Swan Committee (Department of Oncology)
- Oxford ECMC Lead
- Chair of Examiners, Masters in Experimental Therapeutics
Investigating post-transcriptional mechanisms that drive cancer behaviour and researching novel cancer therapeutics for patients with advanced malignancies.
Following medical training, Sarah undertook subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, London. Sarah was awarded a CRUK Junior Clinician Scientist PhD fellowship to study fruit fly genetics at Cambridge University (2000-2004) and later held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.
She was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 and established her laboratory studying the dysregulation of mRNA translation in cancer. In 2015 she moved to Oxford University as an Associate Professor of Experimental Oncology and was director of the Early Phase Clinical Trials Unit until 2021. She is Oxford's ECMC lead and runs a research group in the Old Road Campus Research Building. In July 2021, Sarah took over leadership of the Oxford Clinical Trials Office (OCTO). She has been chief or principal investigator for a number of national and international clinical studies, is involved in cancer prevention and early diagnosis and her research focus is post-transcriptional gene regulation in ovarian cancer.
Lythgoe MP. et al, (2023), Lancet oncol, 24, 963 - 966
Luke JJ. et al, (2023), Br j cancer
Kristeleit R. et al, (2023), British journal of cancer
Lythgoe MP. et al, (2023), The lancet oncology, 24, e150 - e160
Oza AM. et al, (2023)